CN102784096B - A kind of Asiatic acid self-microemulsifyindrug drug delivery system and preparation method thereof - Google Patents
A kind of Asiatic acid self-microemulsifyindrug drug delivery system and preparation method thereof Download PDFInfo
- Publication number
- CN102784096B CN102784096B CN201110129337.9A CN201110129337A CN102784096B CN 102784096 B CN102784096 B CN 102784096B CN 201110129337 A CN201110129337 A CN 201110129337A CN 102784096 B CN102784096 B CN 102784096B
- Authority
- CN
- China
- Prior art keywords
- asiatic acid
- microemulsifyindrug
- delivery system
- drug delivery
- emulsifying agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 title claims abstract description 48
- 229940011658 asiatic acid Drugs 0.000 title claims abstract description 48
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 title claims abstract description 48
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 238000012377 drug delivery Methods 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 36
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 29
- 239000007957 coemulsifier Substances 0.000 claims abstract description 28
- 238000003756 stirring Methods 0.000 claims abstract description 6
- 239000012467 final product Substances 0.000 claims abstract description 3
- 239000003921 oil Substances 0.000 claims description 27
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- -1 polyoxyethylene Polymers 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
- 239000007901 soft capsule Substances 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 230000003064 anti-oxidating effect Effects 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- 239000004359 castor oil Substances 0.000 claims description 4
- 235000019438 castor oil Nutrition 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- 125000005456 glyceride group Chemical group 0.000 claims description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 4
- 235000006408 oxalic acid Nutrition 0.000 claims description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- 239000005642 Oleic acid Substances 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- 230000000259 anti-tumor effect Effects 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical class CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- XEUCQOBUZPQUMQ-UHFFFAOYSA-N Glycolone Chemical compound COC1=C(CC=C(C)C)C(=O)NC2=C1C=CC=C2OC XEUCQOBUZPQUMQ-UHFFFAOYSA-N 0.000 claims 1
- UWIULCYKVGIOPW-UHFFFAOYSA-N Glycolone Natural products CCOC1=C(CC=CC)C(=O)N(C)c2c(O)cccc12 UWIULCYKVGIOPW-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 abstract description 14
- 239000004530 micro-emulsion Substances 0.000 abstract description 10
- 239000002245 particle Substances 0.000 abstract description 7
- 238000004945 emulsification Methods 0.000 abstract description 6
- 239000000839 emulsion Substances 0.000 abstract description 5
- 230000002269 spontaneous effect Effects 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 4
- 210000001124 body fluid Anatomy 0.000 abstract description 3
- 239000010839 body fluid Substances 0.000 abstract description 3
- 238000013019 agitation Methods 0.000 description 25
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 17
- 238000005516 engineering process Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000008389 polyethoxylated castor oil Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 2
- 229960001852 saquinavir Drugs 0.000 description 2
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 description 1
- 241000167550 Centella Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 229920001304 Solutol HS 15 Polymers 0.000 description 1
- BQODPTQLXVVEJG-UHFFFAOYSA-N [O].C=C Chemical group [O].C=C BQODPTQLXVVEJG-UHFFFAOYSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 1
- 229940022757 asiaticoside Drugs 0.000 description 1
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 229940035423 ethyl ether Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000001033 granulometry Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940063121 neoral Drugs 0.000 description 1
- 239000012875 nonionic emulsifier Substances 0.000 description 1
- 229940072250 norvir Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229940071462 oralone Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of Asiatic acid self-microemulsifyindrug drug delivery system (AA SMEDDS) and preparation method thereof.Comprising: 0.5%～5% asiatic acid, oil phase 10% 50%, emulsifying agent 30% 75% and co-emulsifier 0% 30%, percentage ratio is mass percent.Preparation method comprises the following steps: weigh appropriate asiatic acid, adds co-emulsifier and the emulsifying agent of recipe quantity, makes it dissolve 25～45 DEG C of stirrings, then according to recipe quantity adds oil phase and other adjuvants, stirs and get final product.The asiatic acid self-emulsifying microemulsion oral preparation composition of the present invention, after oral chance body fluid, spontaneous emulsification becomes the emulsion droplet of its below particle diameter 100nm.Preparation is simple, and medicine stability is good, and bioavailability is high.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, particularly to a kind of Asiatic acid self-microemulsifyindrug drug delivery system and
Its preparation method.
Background technology
Herba Centellae is Umbelliferae Centella plant, and asiatic acid (Asiatic acid, AA) is wherein content
Higher triterpene acids component, has pharmacologically active widely.It is mainly used in early days treating skin trauma,
Along with to its bioactive further investigation, find asiatic acid and derivant thereof have antiinflammatory, antioxidation,
The biological activitys such as antitumor, anti-hepatic fibrosis, pulmonary fibrosis resistant, cardiovascular protection.
The preparation Jixuedaipian of current domestic listing, oral one time 2,3 times on the one, patients clinical is suitable
Answering property is poor.Studies have reported that, asiaticoside changes into asiatic acid in vivo and plays curative effect.Due to long-pending
Snow oxalic acid dissolubility in water is minimum, at present and independent of its preparation research.Speculate that reason is probably
Cause oral administration biaavailability low owing to the water solublity of asiatic acid is poor, thus be necessary that exploitation one is long-pending
The oral formulations of snow oxalic acid, to improve dissolubility and the vivo biodistribution availability of asiatic acid.
Self-microemulsifyindrug drug transfer system (Self-microemulsifying drug delivery system,
SMEDDS) refer to by oil phase, emulsifying agent and coemulsifier formed homogeneous, transparent and drug containing
Solution, under conditions of physiological condition or gentle agitation, due to the existence of emulsifying agent, meets water spontaneous emulsification
Form particle diameter < 100nm oil-in-water emulsion, referred to as self-microemulsifyindrug drug transfer system.SMEDDS
It it is the excellent carrier of the medicine unstable in slightly solubility, water, oral administration biaavailability is low.Along with ciclosporin
Soft capsule (Neoral), ritonavir soft capsule (Norvir) and Saquinavir soft capsule (Fortovase) etc. are certainly
The successful appearance of emulsification preparation, SMEDDS the most also receives much attention as insoluble drug carrier.
SMEDDS, as a kind of novel nano-lipid drug-supplying system, has a lot of advantage.Due to certainly
Microemulsion system is by oil phase, emulsifying agent and co-emulsifier composition, can be greatly improved the dissolubility of medicine.
Simultaneously because self-microemulsion spontaneous emulsification in gastrointestinal tract becomes the emulsion droplet that particle diameter is the least, there is huge specific surface
Long-pending, the dissolution rate of medicine can be improved.And relative to traditional Emulsion, self microemulsifying preparation is stable
Property is preferable.
Summary of the invention
It is poor that the technical problem to be solved in the present invention is aiming at asiatic acid water solublity, bioavailability
Low, lack the defect of asiatic acid preparation at present, it is provided that a kind of asiatic acid self microemulsifying preparation and system thereof
Preparation Method, preparation technology is simple, and the bioavailability of asiatic acid is greatly improved.
A first aspect of the present invention provides a kind of Asiatic acid self-microemulsifyindrug drug delivery system, mainly includes effect
The asiatic acid of amount and oil phase, emulsifying agent and co-emulsifier.Preferably include: 0.5%～5% asiatic acid,
Oil phase 10%-50%, emulsifying agent 30%-75% and co-emulsifier 0%-30%.Preferred described accumulated snow
Oxalic acid self-micro emulsifying medicament delivery system includes: 1%-4% asiatic acid, oil phase 20%-50%, emulsifying agent
30%-60% and co-emulsifier 0%-25%.Percentage ratio is mass percent.
In the present invention, described oil phase can be natural plants oils, or through structure of modification or hydrolysis
After plant oil.Described oil phase can also is that fatty acid lipid.Described oil phase is preferably for being selected from
Octanoic acid/certain herbaceous plants with big flowers acid triglyceride (GTCC), isopropyl myristate (IPM), ethyl oleate, medium-chain fatty acid
Glyceride (MCT), oleic acid polyethyleneglycol glyceride (Labrafil M 1944CS), Masine 35-1
(Masine35-1) one or more and in polypropylene glycol caprylate (Sefsol 218).Preferred oil of the present invention
Acid polyethylene glycol glyceride (Labrafil M 1944CS) is oil phase, its mass percent preferably 40%.
In the present invention, described emulsifying agent is the nonionic emulsifier of high HLB, preferably for selected from poly-
Oxygen ethylene castor oil (Cremophor EL), polyoxyethylene hydrogenated Oleum Ricini (Cremophor RH40), poly-
In ethylene glycol stearate 15 (Solutol HS 15) and Labraso (Labrasol)
One or more.The preferred polyoxyethylene castor oil of the present invention (Cremophor EL) is emulsifying agent.Emulsifying agent
There is the strongest emulsifying capacity, contact energy spontaneous emulsification after body fluid, and medicine to be had by emulsifying agent itself
The biggest solvability, is possible to prevent medicine Precipitation in gastrointestinal tract.
In the present invention, described co-emulsifier can be ethanol, ethylene glycol, Polyethylene Glycol, diethylene glycol
One or more in single base ether, propylene carbonate and propylene glycol.It is preferably selected from dehydrated alcohol, PEG
400 and TC (Transcutol HP) in one or more.The preferred diethyl of the present invention two
Alcohol list ethylether (Transcutol HP) is co-emulsifier.The existing hydrophilic of described co-emulsifier has again parent
Oiliness, co-emulsifier contributes to active component and forms the solution of transparent and homogeneous and keep the stability of solution.
The addition of co-emulsifier is possible not only to reduce interfacial tension, reduces the consumption of co-emulsifier, simultaneously can also
Increase medicine dissolubility in the formulation.
The Asiatic acid self-microemulsifyindrug drug delivery system of the present invention, it is also possible to farther include antioxidant etc..
Antioxidant is preferably such as vitamin C and/or vitamin E, and consumption is less than 5%, and percentage ratio is matter
Amount percentage ratio.
Second aspect present invention provides the preparation method of a kind of Asiatic acid self-microemulsifyindrug drug delivery system.This
Bright Asiatic acid self-microemulsifyindrug drug delivery system can be according to the conventional method system of self-micro emulsifying medicament delivery system
Standby, preparation method preferably comprises the following steps: weigh appropriate asiatic acid, adds recipe quantity
Co-emulsifier and emulsifying agent, make medicine dissolution 25-45 DEG C of stirring, then according to recipe quantity adds oil phase
With other adjuvants, stir and get final product.
The Asiatic acid self-microemulsifyindrug drug delivery system of the present invention, can be made into hard capsule, soft capsule, granule,
Tablet, the dosage form such as oral liquid.
The Asiatic acid self-microemulsifyindrug drug delivery system of the present invention may be used for preparing antiinflammatory, antioxidation, resisting and swell
The medicine of tumor, fibrosis or cardiovascular protection, preferably anti-inflammatory, antioxidation, antitumor, anti-liver fiber
Change, pulmonary fibrosis resistant or the medicine of cardiovascular protection, such as treat wound, operation wound, burn,
Keloid or sclerodermatous medicine.
Raw material used by the present invention or reagent are in addition to special instruction, the most commercially.
Compared to prior art, beneficial effects of the present invention is as follows: the asiatic acid self-emulsifying microemulsion of the present invention
Meeting body fluid spontaneous emulsification after drug-supplying system is oral in gastrointestinal tract becomes particle diameter at the emulsion droplet of 10～100nm, shows
Write dissolubility and the bioavailability improving asiatic acid, improve clinical drug curative effect, for asiatic acid
Exploitation provides wide prospect.The Asiatic acid self-microemulsifyindrug drug delivery system preparation of the present invention is simple, medicine
Thing good stability.
Accompanying drawing explanation
Below in conjunction with accompanying drawing, inventive feature and beneficial effect are described.
Fig. 1 is particle size distribution after AA-SMEDDS dilution.
Fig. 2 is AA-SMEDDS transmission electron microscope photo (amplification: 20000).
Fig. 3 is that rat oral gavage is dense to average blood medicine internal after AA-SMEDDS and AA crude drug suspension
Degree-time graph (ng/ml, n=5).
Detailed description of the invention
Further illustrate the present invention by embodiment below, but the present invention is not intended to be limited thereto.Following enforcement
The experimental technique of unreceipted actual conditions in example, generally according to normal condition, or is built according to manufacturer
The condition of view.
Embodiment 1
Prescription forms:
Preparation technology:
Weigh the medicine of recipe quantity, add co-emulsifier and the emulsifying agent of recipe quantity, spend water-bath at 37 DEG C
Middle magnetic agitation uniformly makes it dissolve, and adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation is uniform.
Physicochemical property: use Nicomp-380/ZLS laser granulometry to measure asiatic acid self-microemulsion
Particle diameter after dilution and zeta potential, Fig. 1 is shown in particle diameter distribution；NDJ-8S viscometer is used to measure Herba Centellae
Acid self-microemulsion viscosity.
The physicochemical property of table 1. asiatic acid self-microemulsion
Outward appearance:
Take 500 times of volumes of AA-SMEDDS is preheated to 37 DEG C of distilled water dilutings, shakes up gently,
Point sample, phosphotungstic acid negative staining, transmission electron microscope observing result shows that AA-SMEDDS is formed after water dilutes
Uniform oil-in-water type emulsion droplet.Fig. 2 is shown in by transmission electron microscopy picture.
Asiatic acid is administered orally self-microemulsion drug-supplying system pharmacokinetic characteristics:
Take SD male rat 10, be randomly divided into 2 groups.First group of according to dosage 12mg/Kg body weight filling
Stomach, to asiatic acid self-microemulsion, presses identical dosage gavage to asiatic acid suspension for second group.After administration
In 0,5,15,30,60,120,240,360,480,720min posterior orbit take blood, 10000rpm/min
Lower centrifugal, take determination of plasma drug level.Using asiatic acid crude drug suspension as comparison.Blood medicine is dense
Degree-time graph is shown in that Fig. 3, main pharmacokinetic parameters are shown in Table 2, and result shows asiatic acid self-microemulsion, inhales
Receive rapidly, significantly improve the bioavailability in rat body.
The pharmacokinetic parameters (n=5) of table 2. rat oral gavage AA-SMEDDS and AA crude drug suspension
Embodiment 2
Prescription forms:
Preparation technology:
Weigh the medicine of recipe quantity, add co-emulsifier and the emulsifying agent of recipe quantity, in 37 DEG C of water-baths
Magnetic agitation uniformly makes it dissolve, and adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation is uniform.
Embodiment 3
Prescription forms:
Asiatic acid 500mg
Oleic acid polyethyleneglycol glyceride (Labrafil M 1944CS) 3g
Polyoxyethylene castor oil (Cremophor EL) 7g
Preparation technology:
Weigh the medicine of recipe quantity, add co-emulsifier and the emulsifying agent of recipe quantity, in 37 DEG C of water-baths
Magnetic agitation uniformly makes it dissolve, and adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation is uniform.
Embodiment 4
Prescription forms:
Preparation technology:
Weigh the medicine of recipe quantity, add co-emulsifier and the emulsifying agent of recipe quantity, in 37 DEG C of water-baths
Magnetic agitation uniformly makes it dissolve, and adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation is uniform.
Embodiment 5
Prescription forms:
Preparation technology:
Weigh the medicine of recipe quantity, add co-emulsifier and the emulsifying agent of recipe quantity, in 37 DEG C of water-baths
Magnetic agitation uniformly makes it dissolve, and adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation is uniform.
Embodiment 6
Prescription forms:
Preparation technology:
Weigh the medicine of recipe quantity, add co-emulsifier and the emulsifying agent of recipe quantity, in 37 DEG C of water-baths
Magnetic agitation uniformly makes it dissolve, and adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation is uniform.
Embodiment 7
Prescription forms:
Preparation technology:
Weigh the medicine of recipe quantity, add co-emulsifier and the emulsifying agent of recipe quantity, in 37 DEG C of water-baths
Magnetic agitation uniformly makes it dissolve, and adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation is uniform.
Embodiment 8
Preparation technology:
Weigh the medicine of recipe quantity, add co-emulsifier and the emulsifying agent of recipe quantity, in 37 DEG C of water-baths
Magnetic agitation uniformly makes it dissolve, and adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation is uniformly
Can.
Embodiment 9
Prescription forms:
Preparation technology:
Weigh the medicine of recipe quantity, add co-emulsifier and the emulsifying agent of recipe quantity, in 37 DEG C of water-baths
Magnetic agitation uniformly makes it dissolve, and adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation is uniform.
Embodiment 10
Preparation technology:
Weigh the medicine of recipe quantity, add co-emulsifier and the emulsifying agent of recipe quantity, in 37 DEG C of water-baths
Magnetic agitation uniformly makes it dissolve, and adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation is uniform.
Embodiment 11
Prescription forms:
Preparation technology:
Weigh the medicine of recipe quantity, add co-emulsifier and the emulsifying agent of recipe quantity, in 37 DEG C of water-baths
Magnetic agitation uniformly makes it dissolve, and adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation is uniform.
Embodiment 12
Prescription forms:
Preparation technology:
Weigh the medicine of recipe quantity, add co-emulsifier and the emulsifying agent of recipe quantity, in 37 DEG C of water-baths
Magnetic agitation uniformly makes it dissolve, and adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation is uniform.
Claims (6)
1. an Asiatic acid self-microemulsifyindrug drug delivery system, it is characterised in that including: 0.5%～5% amasss
Snow oxalic acid, oil phase 10%-50%, emulsifying agent 30%-75% and co-emulsifier 0%-30%, percentage ratio is matter
Amount percentage ratio；
Described oil phase is oleic acid polyethyleneglycol glyceride；
Described emulsifying agent is hard selected from polyoxyethylene castor oil, polyoxyethylene hydrogenated Oleum Ricini, Polyethylene Glycol
One or more in fat acid ester 15 and Labraso；
Described co-emulsifier selected from ethanol, ethylene glycol, Polyethylene Glycol, TC, third
One or more in olefinic carbon acid esters and propylene glycol.
2. Asiatic acid self-microemulsifyindrug drug delivery system as claimed in claim 1, it is characterised in that institute
The Asiatic acid self-microemulsifyindrug drug delivery system stated, still further comprises antioxidant.
3. Asiatic acid self-microemulsifyindrug drug delivery system as claimed in claim 2, it is characterised in that anti-
Oxidant is vitamin C and/or vitamin E, and consumption is less than 5%, and percentage ratio is mass percent.
4. the Asiatic acid self-microemulsifyindrug drug delivery system as described in any one of claims 1 to 3, its feature
Being, described Asiatic acid self-microemulsifyindrug drug delivery system is hard capsule, soft capsule, granule, tablet
Or oral liquid formulation.
5. the system of the Asiatic acid self-microemulsifyindrug drug delivery system as described in any one of Claims 1 to 4
Preparation Method, it is characterised in that comprise the following steps: weigh asiatic acid, add recipe quantity helps emulsifying
Agent and emulsifying agent, make it dissolve 25～45 DEG C of stirrings, then according to recipe quantity adds oil phase and other are auxiliary
Material, stirs and get final product.
6. the Asiatic acid self-microemulsifyindrug drug delivery system as described in any one of Claims 1 to 4 is anti-in preparation
Application in the medicine of inflammation, antioxidation, antitumor, fibrosis or cardiovascular protection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110129337.9A CN102784096B (en) | 2011-05-18 | 2011-05-18 | A kind of Asiatic acid self-microemulsifyindrug drug delivery system and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110129337.9A CN102784096B (en) | 2011-05-18 | 2011-05-18 | A kind of Asiatic acid self-microemulsifyindrug drug delivery system and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102784096A CN102784096A (en) | 2012-11-21 |
| CN102784096B true CN102784096B (en) | 2016-10-12 |
Family
ID=47149819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110129337.9A Active CN102784096B (en) | 2011-05-18 | 2011-05-18 | A kind of Asiatic acid self-microemulsifyindrug drug delivery system and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102784096B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105878815A (en) * | 2016-06-24 | 2016-08-24 | 凌云 | Traditional Chinese medicinal self-microemulsion fast-release drop pill for treating coronary heart disease and preparation method |
| CN106038930A (en) * | 2016-06-24 | 2016-10-26 | 凌云 | Traditional Chinese medicine fast release droppill for treating venomous snake bite and preparation method thereof |
| CN105943604A (en) * | 2016-06-24 | 2016-09-21 | 赵晶晶 | Self-microemulsion rapid-release compound Danshen dripping pill and preparation method |
| CN105943687A (en) * | 2016-06-24 | 2016-09-21 | 赵晶晶 | Traditional Chinese medicine self-microemulsion instant release pill for treating angina pectoris and preparation method thereof |
| CN105943640A (en) * | 2016-06-24 | 2016-09-21 | 安徽高山药业有限公司 | Traditional Chinese medicine self-microemulsion instant release pill for treating myocardial ischemia and preparation method thereof |
| CN111840223A (en) * | 2019-04-22 | 2020-10-30 | 上海现代药物制剂工程研究中心有限公司 | Alisol A self-microemulsion composition and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1582946A (en) * | 2004-06-09 | 2005-02-23 | 崔福贵 | Use of centellosic acid derivative in preparation of medicines for diseases of cardio-cerebral blood vessels |
| CN101474157A (en) * | 2009-01-19 | 2009-07-08 | 浙江省医学科学院 | Asiatic acid injectable sustained-release microballoons and preparation method thereof |
| CN101991532A (en) * | 2009-08-14 | 2011-03-30 | 上海开拓者医药发展有限公司 | Self-microemulsion composition, microemulsion and preparation methods thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1228042C (en) * | 2003-01-30 | 2005-11-23 | 上海家化联合股份有限公司 | Asiaticoside liposome and its use |
| CA2573494A1 (en) * | 2004-07-14 | 2006-01-26 | Gary R. Eldridge | Control of biofilm formation |
-
2011
- 2011-05-18 CN CN201110129337.9A patent/CN102784096B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1582946A (en) * | 2004-06-09 | 2005-02-23 | 崔福贵 | Use of centellosic acid derivative in preparation of medicines for diseases of cardio-cerebral blood vessels |
| CN101474157A (en) * | 2009-01-19 | 2009-07-08 | 浙江省医学科学院 | Asiatic acid injectable sustained-release microballoons and preparation method thereof |
| CN101991532A (en) * | 2009-08-14 | 2011-03-30 | 上海开拓者医药发展有限公司 | Self-microemulsion composition, microemulsion and preparation methods thereof |
Non-Patent Citations (1)
| Title |
|---|
| 齐墩果酸自微乳化给药系统的制备及其体外溶出度考察;杨蕊等;《中国药房》;20101231;第21卷(第33期);第3128-3130页，尤其是第3129页左栏第2.1节、第3130页左栏第2.3.9节第(2)段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102784096A (en) | 2012-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2257917C2 (en) | Self-emulsifying composition for scarcely water-soluble medicament | |
| CN102784096B (en) | A kind of Asiatic acid self-microemulsifyindrug drug delivery system and preparation method thereof | |
| TW200422057A (en) | Composition in form of emulsion or microemulsion pre-concentrate for oral administration and its uses | |
| EP0825849A1 (en) | Self-emulsifying formulations of lipophilic drugs | |
| WO2020147416A1 (en) | Terpene pharmaceutical composition self-emulsifying oral preparation, preparation method therefor and use thereof | |
| CN101439015B (en) | Pharmaceutical composition with enhanced bioavailability | |
| JP2003500454A (en) | Substantially oil-free cyclosporin composition | |
| CN100536921C (en) | Supersaturated cationic self-emulsifying drug delivery system and preparation method thereof | |
| US9278065B2 (en) | Delivery systems for solubilising water-insoluble pharmaceutical active ingredients | |
| CN101780037B (en) | Dipyridamole self-emulsifying medicament administration system and preparation method thereof | |
| AU2007333355B2 (en) | Microemulsion dosage forms of valsartan and methods of making the same | |
| CN101103962A (en) | Vinpocetine oral self-microemulsion drug delivery system and preparation method thereof | |
| WO2025087032A1 (en) | Fenofibrate oily formulation, oral drug, and preparation method | |
| EP1151755A1 (en) | Pharmaceutical compositions comprising cyclosporin as active ingredient | |
| US5945398A (en) | Pharmaceutical compositions containing cyclosporin | |
| KR20140018858A (en) | Pharmaceutical compositions comprising alisporivir | |
| US6346511B1 (en) | Pharmaceutical composition comprising cyclosporin | |
| CN100515427C (en) | Breviscapine self-emulsifying soft capsule and preparation method thereof | |
| CN102008471B (en) | Lacidipine self-microemulsifying soft capsules and preparation method thereof | |
| CN102727608A (en) | Nadolol-apple seed oil nanoemulsion antihypertensive drug | |
| CN100435783C (en) | Orally administered composition containing fat soluble ingredient of red sage root | |
| CN1686156A (en) | Clamycin structurization emulsion composition | |
| AP1040A (en) | A novel composition containing cyclosporin. | |
| KR20070018003A (en) | Microemulsion formulations containing certain substance P antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |